Eliquis Approved to Treat Deep Vein Thrombosis
August 25, 2014 - Eliquis (apixaban) is manufactured by Bristol-Myers Squibb and Pfizer and received an expanded approval from the Food and Drug Administration (FDA) for the treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and to help reduce the risk of recurrence. Eliquis was approved by the FDA in December 2012 to reduce the risk of DVT and PE for people who have had knee surgery and hip replacement.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.